Esophageal Neoplasm

Curated

← investigated for

Vinorelbinesmall_molecule

unknown

Curated

← investigated for

Trastuzumabmonoclonal_antibody

unknown

Curated

← investigated for

Toripalimabmonoclonal_antibody

unknown

Curated

← investigated for

Tegafursmall_molecule

unknown

Curated

← investigated for

Sugemalimabmonoclonal_antibody

unknown

Curated

← investigated for

Sintilimabmonoclonal_antibody

unknown

Curated

← investigated for

Serplulimabmonoclonal_antibody

unknown

Curated

← investigated for

Regorafenib Anhydroussmall_molecule

unknown

Curated

← investigated for

Regorafenibsmall_molecule

unknown

Curated

← investigated for

Pertuzumabmonoclonal_antibody

unknown

Curated

← investigated for

Pembrolizumabmonoclonal_antibody

unknown

Curated

← investigated for

Pegfilgrastimother

unknown

Curated

← investigated for

Paclitaxelsmall_molecule

unknown

Curated

← investigated for

Oxaliplatinsmall_molecule

unknown

Curated

← investigated for

Nivolumabmonoclonal_antibody

unknown

Curated

← investigated for

Nimotuzumabmonoclonal_antibody

unknown

Curated

← investigated for

Nedaplatinsmall_molecule

unknown

Curated

← investigated for

Levoleucovorinsmall_molecule

unknown

Curated

← investigated for

Leucovorinsmall_molecule

unknown

Curated

← investigated for

Lenvatinibsmall_molecule

unknown

Curated

← investigated for

Irinotecansmall_molecule

unknown

Curated

← investigated for

Fluorouracilsmall_molecule

unknown

Curated

← investigated for

Erlotinib Hydrochloridesmall_molecule

unknown

Curated

← investigated for

Erlotinibsmall_molecule

unknown

Curated

← investigated for

Epirubicinsmall_molecule

unknown

Curated

← investigated for

Durvalumabmonoclonal_antibody

unknown

Curated

← investigated for

Docetaxelsmall_molecule

unknown

Curated

← investigated for

Cisplatinsmall_molecule

unknown

Curated

← investigated for

Cetuximabmonoclonal_antibody

unknown

Curated

← investigated for

Carboplatinsmall_molecule

unknown

Curated

← investigated for

Capecitabinesmall_molecule

unknown

Curated

← investigated for

Camrelizumabmonoclonal_antibody

unknown

Curated

← investigated for

Atezolizumabmonoclonal_antibody

unknown

Curated

← investigated for

Aspirinsmall_molecule

unknown

Curated

← investigated for

Trastuzumab Deruxtecanadc

unknown

Curated

← investigated for

Trastuzumab Deruxtecanadc

unknown

Curated

← investigated for

Thalidomidesmall_molecule

unknown

Curated

← investigated for

Sunitinibsmall_molecule

unknown

Curated

← investigated for

Sacituzumab Govitecanadc

unknown

Curated

← investigated for

Rigosertibsmall_molecule

unknown

Curated

← investigated for

Retifanlimabmonoclonal_antibody

unknown

Curated

← investigated for

Ramucirumabmonoclonal_antibody

unknown

Curated

← investigated for

Raltitrexedsmall_molecule

unknown

Curated

← investigated for

Poziotinibsmall_molecule

unknown

Curated

← investigated for

Pemetrexedsmall_molecule

unknown

Curated

← investigated for

Panitumumabmonoclonal_antibody

unknown

Curated

← investigated for

Palbociclibsmall_molecule

unknown

Curated

← investigated for

Metforminsmall_molecule

unknown

Curated

← investigated for

Lapatinibsmall_molecule

unknown

Curated

← investigated for

Ipilimumabmonoclonal_antibody

unknown

Curated

← investigated for

Icotinibsmall_molecule

unknown

Curated

← investigated for

Ibrutinibsmall_molecule

unknown

Curated

← investigated for

Hydroxyureasmall_molecule

unknown

Curated

← investigated for

Hydroxycarbamidesmall_molecule

unknown

Curated

← investigated for

Gemcitabinesmall_molecule

unknown

Curated

← investigated for

Gefitinibsmall_molecule

unknown

Curated

← investigated for

Fruquintinibsmall_molecule

unknown

Curated

← investigated for

Fludarabinesmall_molecule

unknown

Curated

← investigated for

Filgrastimother

unknown

Curated

← investigated for

Doxorubicinsmall_molecule

unknown

Curated

← investigated for

Decitabinesmall_molecule

unknown

Curated

← investigated for

Cyclophosphamidesmall_molecule

unknown

Curated

← investigated for

Celecoxibsmall_molecule

unknown

Curated

← investigated for

Buparlisibsmall_molecule

unknown

Curated

← investigated for

Bortezomibsmall_molecule

unknown

Curated

← investigated for

Bevacizumabmonoclonal_antibody

unknown

Curated

← investigated for

Avelumabmonoclonal_antibody

unknown

Curated

← investigated for

Arsenic Trioxidesmall_molecule

unknown

Curated

← investigated for

Alvocidibsmall_molecule

unknown

Curated

← investigated for

Afatinibsmall_molecule

unknown

Curated

← investigated for

Adebrelimabmonoclonal_antibody

unknown

Curated

← investigated for

Vorinostatsmall_molecule

unknown

Curated

← investigated for

Vandetanibsmall_molecule

unknown

Curated

← investigated for

Tremelimumabmonoclonal_antibody

unknown

Curated

← investigated for

Topotecansmall_molecule

unknown

Curated

← investigated for

Sorafenib Tosylatesmall_molecule

unknown

Curated

← investigated for

Sorafenibsmall_molecule

unknown

Curated

← investigated for

Sonidegibsmall_molecule

unknown

Curated

← investigated for

Olaparibsmall_molecule

unknown

Curated

← investigated for

Motesanibsmall_molecule

unknown

Curated

← investigated for

Ganetespibsmall_molecule

unknown

Curated

← investigated for

Everolimussmall_molecule

unknown

Curated

← investigated for

Eprenetapoptsmall_molecule

unknown

Curated

← investigated for

Dexamethasonesmall_molecule

unknown

Curated

← investigated for

Cobimetinibsmall_molecule

unknown

Curated

← investigated for

Azacitidinesmall_molecule

unknown

Curated

← investigated for

Alpelisibsmall_molecule

unknown

Curated

Esophageal Neoplasm altered in cohorts of …ALTERED_INderived15 of 136show all (up to 200)
← altered in cohorts of	TP53 167 / 185 cases (90 %) · ssm · TCGA-ESCA · largest of 7 cohorts	—	—	Esophageal Carcinoma	7	Observed	gdc	graph →
← altered in cohorts of	MYC 138 / 185 cases (75 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	POU5F1B 138 / 185 cases (75 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TG 138 / 185 cases (75 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	KCNQ3 135 / 185 cases (73 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ADCY8 134 / 185 cases (72 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CDKN2A 134 / 185 cases (72 %) · ssm · TCGA-ESCA · largest of 3 cohorts	—	—	Esophageal Carcinoma	3	Observed	gdc	graph →
← altered in cohorts of	GSDMC 134 / 185 cases (72 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	LRATD2 134 / 185 cases (72 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CDKN2B 133 / 185 cases (72 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	EFR3A 133 / 185 cases (72 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ASAP1 132 / 185 cases (71 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CCN4 132 / 185 cases (71 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	HHLA1 132 / 185 cases (71 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	KHDRBS3 132 / 185 cases (71 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →

Esophageal Neoplasm altered in cohorts of …ALTERED_INderived15 of 136show all (up to 200)

← altered in cohorts of

TP53

167 / 185 cases (90 %) · ssm · TCGA-ESCA · largest of 7 cohorts

—

Observed

← altered in cohorts of

MYC

138 / 185 cases (75 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

POU5F1B

138 / 185 cases (75 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

138 / 185 cases (75 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

KCNQ3

135 / 185 cases (73 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

ADCY8

134 / 185 cases (72 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

CDKN2A

134 / 185 cases (72 %) · ssm · TCGA-ESCA · largest of 3 cohorts

—

Observed

← altered in cohorts of

GSDMC

134 / 185 cases (72 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

LRATD2

134 / 185 cases (72 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

CDKN2B

133 / 185 cases (72 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

EFR3A

133 / 185 cases (72 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

ASAP1

132 / 185 cases (71 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

CCN4

132 / 185 cases (71 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

HHLA1

132 / 185 cases (71 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

KHDRBS3

132 / 185 cases (71 %) · ssm · TCGA-ESCA

—

Observed

Esophageal Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 149show all (up to 200)
→ investigated in trials for	Cisplatinsmall_molecule 156 trials (31 active) · roll-up of the cancer and its descendants	—	—	Esophageal Neoplasm	156	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall_molecule 137 trials (38 active) · roll-up of the cancer and its descendants	—	—	Esophageal Neoplasm	137	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall_molecule 132 trials (27 active) · roll-up of the cancer and its descendants	—	—	Esophageal Neoplasm	132	Observed	clinicaltrials	graph →
→ investigated in trials for	Oxaliplatinsmall_molecule 85 trials (20 active) · roll-up of the cancer and its descendants	—	—	Esophageal Neoplasm	85	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall_molecule 74 trials (28 active) · roll-up of the cancer and its descendants	—	—	Esophageal Neoplasm	74	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall_molecule 70 trials (11 active) · roll-up of the cancer and its descendants	—	—	Esophageal Neoplasm	70	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal_antibody 66 trials (24 active) · roll-up of the cancer and its descendants	—	—	Esophageal Neoplasm	66	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall_molecule 64 trials (12 active) · roll-up of the cancer and its descendants	—	—	Esophageal Neoplasm	64	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall_molecule 55 trials (16 active) · roll-up of the cancer and its descendants	—	—	Esophageal Neoplasm	55	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall_molecule 52 trials (15 active) · roll-up of the cancer and its descendants	—	—	Esophageal Neoplasm	52	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal_antibody 41 trials (25 active) · roll-up of the cancer and its descendants	—	—	Esophageal Neoplasm	41	Observed	clinicaltrials	graph →
→ investigated in trials for	Tislelizumabmonoclonal_antibody 40 trials (24 active) · roll-up of the cancer and its descendants	—	—	Esophageal Neoplasm	40	Observed	clinicaltrials	graph →
→ investigated in trials for	Chemotherapy 32 trials (18 active) · roll-up of the cancer and its descendants	—	—	Esophageal Neoplasm	32	Observed	clinicaltrials	graph →
→ investigated in trials for	Camrelizumabmonoclonal_antibody 31 trials (9 active) · roll-up of the cancer and its descendants	—	—	Esophageal Neoplasm	31	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 31 trials (16 active) · roll-up of the cancer and its descendants	—	—	Esophageal Neoplasm	31	Observed	clinicaltrials	graph →

Esophageal Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 149show all (up to 200)

→ investigated in trials for

Cisplatinsmall_molecule

156 trials (31 active) · roll-up of the cancer and its descendants

—

156

Observed

→ investigated in trials for

Paclitaxelsmall_molecule

137 trials (38 active) · roll-up of the cancer and its descendants

—

137

Observed

→ investigated in trials for

Fluorouracilsmall_molecule

132 trials (27 active) · roll-up of the cancer and its descendants

—

132

Observed

→ investigated in trials for

Oxaliplatinsmall_molecule

85 trials (20 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall_molecule

74 trials (28 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Irinotecansmall_molecule

70 trials (11 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal_antibody

66 trials (24 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Docetaxelsmall_molecule

64 trials (12 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Capecitabinesmall_molecule

55 trials (16 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Leucovorinsmall_molecule

52 trials (15 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal_antibody

41 trials (25 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tislelizumabmonoclonal_antibody

40 trials (24 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Chemotherapy

32 trials (18 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Camrelizumabmonoclonal_antibody

31 trials (9 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nab-paclitaxel

31 trials (16 active) · roll-up of the cancer and its descendants

—

Observed

Esophageal Neoplasm studied in …STUDIED_INderived10 of 2,208show all (up to 200)
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 2,208 trials mapped (718 active)	—	—	Esophageal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05891171Phase 1 · active not recruiting Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers · condition mapped CURATED_EXACT · 2,208 trials mapped (718 active)	—	—	Malignant Esophageal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06203600Phase 2/Phase 3 · recruiting Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial · condition mapped CURATED_BROADER · 2,208 trials mapped (718 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07212491enrolling by invitation Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 2,208 trials mapped (718 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07578571Phase 1 · recruiting A Phase 1 Study of IM-1617 in Participants With Advanced Cancer · condition mapped CURATED_EXACT · 2,208 trials mapped (718 active)	—	—	Malignant Esophageal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07603375Phase 2 · recruiting Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 2,208 trials mapped (718 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04415853Phase 3 · recruiting Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer · condition mapped CURATED_EXACT · 2,208 trials mapped (718 active)	—	—	Malignant Esophageal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · condition mapped ONTOLOGY_EXACT · 2,208 trials mapped (718 active)	—	—	Esophageal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05048368Phase 1 · withdrawn Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function · condition mapped CURATED_EXACT · 2,208 trials mapped (718 active)	—	—	Malignant Esophageal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05965999recruiting Lucid Registry Study · condition mapped ONTOLOGY_EXACT · 2,208 trials mapped (718 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →

Esophageal Neoplasm studied in …STUDIED_INderived10 of 2,208show all (up to 200)

→ studied in

NCT02465060Phase 2 · active not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 2,208 trials mapped (718 active)

—

Observed

→ studied in

NCT05891171Phase 1 · active not recruiting

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers · condition mapped CURATED_EXACT · 2,208 trials mapped (718 active)

—

Observed

Esophageal Adenocarcinoma

→ studied in

NCT06203600Phase 2/Phase 3 · recruiting

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial · condition mapped CURATED_BROADER · 2,208 trials mapped (718 active)

—

Observed

Esophageal Adenocarcinoma

→ studied in

NCT07212491enrolling by invitation

Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 2,208 trials mapped (718 active)

—

Observed

→ studied in

NCT07578571Phase 1 · recruiting

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer · condition mapped CURATED_EXACT · 2,208 trials mapped (718 active)

—

Observed

Esophageal Adenocarcinoma

→ studied in

NCT07603375Phase 2 · recruiting

Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 2,208 trials mapped (718 active)

—

Observed

→ studied in

NCT04415853Phase 3 · recruiting

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer · condition mapped CURATED_EXACT · 2,208 trials mapped (718 active)

—

Observed

→ studied in

NCT05007106Phase 2 · completed

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · condition mapped ONTOLOGY_EXACT · 2,208 trials mapped (718 active)

—

Observed

→ studied in

NCT05048368Phase 1 · withdrawn

Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function · condition mapped CURATED_EXACT · 2,208 trials mapped (718 active)

—

Observed